Glutamine/glutamate metabolism rewiring in reprogrammed human hepatocyte-like cells.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
29 11 2019
Historique:
received: 31 12 2018
accepted: 13 11 2019
entrez: 1 12 2019
pubmed: 1 12 2019
medline: 11 11 2020
Statut: epublish

Résumé

Human dermal fibroblasts can be reprogrammed into hepatocyte-like (HEP-L) cells by the expression of a set of transcription factors. Yet, the metabolic rewiring suffered by reprogrammed fibroblasts remains largely unknown. Here we report, using stable isotope-resolved metabolic analysis in combination with metabolomic-lipidomic approaches that HEP-L cells mirrors glutamine/glutamate metabolism in primary cultured human hepatocytes that is very different from parental human fibroblasts. HEP-L cells diverge glutamine from multiple metabolic pathways into deamidation and glutamate secretion, just like periportal hepatocytes do. Exceptionally, glutamine contribution to lipogenic acetyl-CoA through reductive carboxylation is increased in HEP-L cells, recapitulating that of primary cultured human hepatocytes. These changes can be explained by transcriptomic rearrangements of genes involved in glutamine/glutamate metabolism. Although metabolic changes in HEP-L cells are in line with reprogramming towards the hepatocyte lineage, our conclusions are limited by the fact that HEP-L cells generated do not display a complete mature phenotype. Nevertheless, our findings are the first to characterize metabolic adaptation in HEP-L cells that could ultimately be targeted to improve fibroblasts direct reprogramming to HEP-L cells.

Identifiants

pubmed: 31784643
doi: 10.1038/s41598-019-54357-x
pii: 10.1038/s41598-019-54357-x
pmc: PMC6884617
doi:

Substances chimiques

Glutamine 0RH81L854J
Glutamic Acid 3KX376GY7L

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17978

Références

Cell Metab. 2019 Sep 3;30(3):594-606.e3
pubmed: 31257152
Cell Transplant. 2008;17(10-11):1211-9
pubmed: 19181215
Biochem J. 1935 Aug;29(8):1951-69
pubmed: 16745865
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19345-50
pubmed: 18032601
Sci Rep. 2016 Jun 06;6:27239
pubmed: 27265840
Anal Chem. 2011 Dec 1;83(23):9114-22
pubmed: 22004349
FEBS J. 2012 Aug;279(15):2598-609
pubmed: 22672505
Cell Stem Cell. 2014 Mar 6;14(3):370-84
pubmed: 24582927
Eur J Biochem. 1981 Jun 1;116(3):609-14
pubmed: 6266828
Stem Cell Res Ther. 2015 Dec 12;6:246
pubmed: 26652177
J Biol Chem. 1995 Apr 28;270(17):10027-36
pubmed: 7730304
Nat Protoc. 2010 Feb;5(2):267-81
pubmed: 20134427
Pharmacol Ther. 1992;53(3):275-354
pubmed: 1409850
Nature. 2011 Nov 20;481(7381):380-4
pubmed: 22101433
Biochem J. 1955 Dec;61(4):589-600
pubmed: 13276342
PLoS Biol. 2010 Oct 19;8(10):e1000514
pubmed: 21049082
Am J Clin Nutr. 2009 Sep;90(3):857S-861S
pubmed: 19625684
Stem Cell Res Ther. 2016 Jul 27;7(1):96
pubmed: 27460218
J Nutr. 2000 Apr;130(4S Suppl):983S-7S
pubmed: 10736366
Sci Rep. 2017 Nov 30;7(1):16675
pubmed: 29192290
Liver Transpl. 2015 Jun;21(6):801-11
pubmed: 25821167
Nature. 2017 Feb 16;542(7641):352-356
pubmed: 28166538
Cell Res. 2019 Sep;29(9):696-710
pubmed: 31270412
J Biol Chem. 1994 Nov 4;269(44):27179-82
pubmed: 7961626
Am J Physiol. 1999 Oct;277(4):F477-80
pubmed: 10516268
Methods Enzymol. 2015;561:303-30
pubmed: 26358909
Cell Stem Cell. 2008 Jan 10;2(1):90-102
pubmed: 18371425
BMC Bioinformatics. 2016 Nov 25;17(1):485
pubmed: 27887574
J Biol Chem. 2008 Jul 25;283(30):20621-7
pubmed: 18364355
Eur J Biochem. 1983 Nov 2;136(2):421-5
pubmed: 6414814
J Biol Chem. 1965 Feb;240:613-7
pubmed: 14275112
Nat Commun. 2013;4:2236
pubmed: 23900562
PLoS One. 2014 Jun 25;9(6):e100134
pubmed: 24963715
J Biol Chem. 1995 Apr 28;270(17):10037-42
pubmed: 7730305
J Nutr. 2008 Oct;138(10):2021S-2024S
pubmed: 18806118
Stem Cells Dev. 2019 Jul 15;28(14):907-919
pubmed: 31122128
Cell Stem Cell. 2014 Mar 6;14(3):394-403
pubmed: 24582926
Biophys J. 2010 Jul 21;99(2):L13-5
pubmed: 20643047

Auteurs

Maria Ballester (M)

Unidad de Hepatología Experimental, CIBERehd, Instituto de Investigación Sanitaria La Fe, Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain.

Enrique Sentandreu (E)

Unidad de Hepatología Experimental, CIBERehd, Instituto de Investigación Sanitaria La Fe, Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain.

Giovanna Luongo (G)

Unidad de Hepatología Experimental, CIBERehd, Instituto de Investigación Sanitaria La Fe, Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain.

Ramon Santamaria (R)

Unidad de Hepatología Experimental, CIBERehd, Instituto de Investigación Sanitaria La Fe, Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain.

Miguel Bolonio (M)

Unidad de Hepatología Experimental, CIBERehd, Instituto de Investigación Sanitaria La Fe, Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain.

Maria Isabel Alcoriza-Balaguer (MI)

Unidad de Biomarcadores y Medicina de Precisión and Unidad Analítica, Instituto de Investigación Sanitaria La Fe, Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain.

Martina Palomino-Schätzlein (M)

Unidad de Descubrimiento de Fármacos, Instituto de Investigación Sanitaria La Fe, Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain.

Antonio Pineda-Lucena (A)

Unidad de Descubrimiento de Fármacos, Instituto de Investigación Sanitaria La Fe, Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain.

Jose Castell (J)

Unidad de Hepatología Experimental, CIBERehd, Instituto de Investigación Sanitaria La Fe, Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain.

Agustin Lahoz (A)

Unidad de Biomarcadores y Medicina de Precisión and Unidad Analítica, Instituto de Investigación Sanitaria La Fe, Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain.

Roque Bort (R)

Unidad de Hepatología Experimental, CIBERehd, Instituto de Investigación Sanitaria La Fe, Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain. bort_ber@gva.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH